AstraZeneca's IL-33-targeting antibody tozorakimab has made the grade in two phase 3 chronic obstructive pulmonary disease (COPD) trials, raising the prospects of a class that has recorded some ...
Recent results from the TETON-1 phase 3 clinical trial assessing inhaled treprostinil to treat idiopathic pulmonary fibrosis ...
Clinical Trials Arena on MSN
AstraZeneca’s COPD drug gains third Phase III win
Positive data from the MIRANDA trial follows the OBERON and TITANIA studies of tozorakimab in COPD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results